Ignite Creation Date:
2024-05-06 @ 8:02 PM
Last Modification Date:
2024-10-26 @ 3:19 PM
Study NCT ID:
NCT06228807
Status:
COMPLETED
Last Update Posted:
2024-02-06
First Post:
2024-01-18
Brief Title:
Clinical Characteristics and Predictors of Adverse Outcomes in HFpEF
Sponsor:
Ya-Wei Xu
Organization:
Shanghai 10th Peoples Hospital
Study Overview
Official Title:
Exploring Clinical Characteristics and Predictors of Adverse Outcomes in Patients Diagnosed With Heart Failure With Preserve Ejection Fraction HFpEF
Status:
COMPLETED
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Heart failure with preserved ejection fraction HFpEF is a prevalent form of heart failure characterized by impaired left ventricle pressures and diastolic dysfunction Despite its increasing prevalence effective treatment options for HFpEF remain limited probably due to its heterogenous underlying pathological etiology involving chronic systemic inflammation and metabolic dysregulation Identifying new predictors of poor prognosis is crucial for risk stratification and tailored management
Detailed Description:
The prognosis for HFpEF is concerning marked by significant mortality and frequent hospital readmissions The exact mechanisms underlying HFpEF remain unresolved The clinical syndrome arises from intricate interactions among various risk factors leading to organ dysfunction and clinical symptoms Common co-morbidities including atrial fibrillation diabetes chronic kidney disease and obesity may influence HFpEF pathophysiology Recent discussions suggest an inflammatory-metabolic phenotype in HFpEF characterized by heightened inflammatory biomarkers insulin resistance hyperglycemia hyperlipidemia microvascular endothelial and vascular dysfunction atherosclerosis consequently leading to significant myocardial damage However there is still a lack of clinical risk predictors associated with metabolic phenotype within HFpEF
The aim of this study is to investigate the impact of parameters reflecting the metabolic phenotype coronary microvascular dysfunction in HFpEF and establish their correlation with clinical outcomes The objective is to identify novel predictors for adverse prognosis in HFpEF potentially serving as targets for drug therapy This research aims to pave the way for targeted drug interventions in cardiometabolic diseases offering new avenues for therapeutic approaches
The aim of this study is to investigate the impact of parameters reflecting the metabolic phenotype coronary microvascular dysfunction in HFpEF and establish their correlation with clinical outcomes The objective is to identify novel predictors for adverse prognosis in HFpEF potentially serving as targets for drug therapy This research aims to pave the way for targeted drug interventions in cardiometabolic diseases offering new avenues for therapeutic approaches
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None